文献速递MDS 与骨髓增殖性肿瘤

芦可替尼对JAK2V617F阳性骨髓增殖性肿瘤细胞基质金属蛋白酶的调控

[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

研究纳入40例初诊JAK2V617F阳性MPN患者与15名健康对照,检测骨髓组织p-JAK2、MMP-2、MMP-9表达,并用芦可替尼干预患者骨髓细胞及HEL细胞系。结果显示MPN组三者表达均高于对照组,MMP-2、MMP-9与JAK2V617F突变呈正相关;芦可替尼呈时间剂量依赖性抑制HEL增殖,降低迁移细胞数及JAK2、MMP-2、MMP-9表达。

要点

  • 初诊MPN组骨髓p-JAK2、MMP-2、MMP-9蛋白表达均高于健康对照组。
  • MMP-2、MMP-9蛋白水平与JAK2V617F突变量呈正相关。
  • 芦可替尼呈时间及剂量依赖性抑制HEL细胞增殖并降低细胞迁移。

核心结论

  • 芦可替尼通过调控JAK2信号通路抑制MMP-2、MMP-9表达,从而抑制MPN细胞迁移能力。

研究设计与样本

  • 研究纳入2012年1月至2015年12月保定市第一医院40例未经治疗的JAK2V617F阳性MPN患者,以15名健康志愿者为对照。
  • 体外用芦可替尼干预JAK2V617F阳性MPN患者骨髓细胞,并以不同浓度芦可替尼(0、50、100、250、500、1000 nmol/L)作用于人红白血病细胞株HEL细胞。
  • 检测方法包括实时荧光定量PCR、免疫组化、CCK-8、Transwell小室和Western blot。

主要发现

  • 初诊MPN组p-JAK2蛋白表达为(78.56±24.55)%,高于对照组的(41.59±17.29)%,P<0.05。
  • 初诊MPN组MMP-2蛋白表达为(48.25±18.74)%,高于对照组的(22.79±13.89)%,P<0.05。
  • 初诊MPN组MMP-9蛋白表达为(53.29±19.28)%,高于对照组的(15.56±14.96)%,P<0.05。
  • MMP-2、MMP-9蛋白水平与JAK2V617F突变量呈正相关(r=0.526,P=0.001;r=0.543,P=0.001)。
  • 5 nmol/L芦可替尼作用24 h后,MPN原代细胞迁移至下室细胞数为154.7±27.5,少于无芦可替尼组的320.3±67.3(t=13.47,P=0.001);HEL细胞为70.7±10.5,少于无芦可替尼组的135.3±16.7(t=13.89,P=0.001)。

关键数值与推荐

  • 芦可替尼呈时间和剂量依赖性抑制HEL细胞增殖。
  • JAK2、MMP-2、MMP-9 mRNA及蛋白表达随芦可替尼剂量增加而降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the regulation of JAK2 tyrosine kinase inhibitor ruxolitinib on extracellular matrix metalloproteinase (MMP in JAK2V617F positive myeloproliferative neoplasms (MPN) cells. Methods: ①Forty cases of newly diagnosed JAK2V617F positive MPN patients and 15 healthy volunteers as control in Baoding No.1 Hospital between January 2012 and December 2015 were enrolled in this study. JAK2V617F/JAK2 ratio was detected by real-time-PCR; the expression levels of phosphorylation protein tyrosine kinase 2 (p-JAK2) , MMP-2 and MMP-9 in pathological tissues of bone marrow were detected by immunohistochemistry. The bone marrow cells of JAK2V617F positive MPN patients were treated with ruxolitinib, then the migration ability and MMP-2, MMP-9 gene and protein expression levels were detected. ②The human erythroleukemia cell line HEL cells were treated with different concentrations of ruxolitinib (0, 50, 100, 250, 500, 1 000 nmol/L) . The cell viability was detected by CCK-8 test; cell migration ability was tested by transwell chambers. The mRNA expression levels of JAK2, MMP-2 and MMP-9 were detected by real-time-PCR. The protein expression levels of p-JAK2, MMP-2 and MMP-9 were detected by Western blot. Results: ①The expression levels of p-JAK2, MMP-2 and MMP-9 in the newly diagnosed group were significantly higher than control group respectively [ (78.56±24.55) % vs (41.59±17.29) %, P<0.05; (48.25±18.74) % vs (22.79±13.89) %, P<0.05; (53.29±19.28) % vs (15.56±14.96) %, P<0.05]. Spearman correlation analysis showed the positive correlation of MMP-2 and MMP-9 protein expression levels with JAK2V617F mutation (r=0.526, P=0.001; r=0.543, P=0.001) . ②The proliferation of HEL cells was inhibited by different concentrations of ruxolitinib in time and dose dependent manner. ③Cell migration test showed the number of cells leaked to the low chamber in MPN patients bone marrow cells and HEL cells treated with 5 nmol/L of ruxolitinib group were significantly lower than that without ruxolitinib treatment after 24 h [ (154.7±27.5) vs (320.3±67.3) , t=13.47, P<0.05; (70.7±10.5) vs (135.3±16.7) , t=13.89, P<0.05]. The mRNA and protein expression levels of JAK2, MMP-2 and MMP-9 decreased with the increased concentration of ruxolitinib. Conclusion: Ruxolitinib inhibits MPN cell migration and expression of MMP-2 and MMP-9 via JAK2 signal pathway. 目的:探讨JAK2抑制剂Ruxolitinib对JAK2V617F突变阳性的骨髓增殖性肿瘤(MPN)细胞内基质金属蛋白酶(MMP)调控的影响。 方法: ①收集2012年1月到2015年12月保定市第一医院收治的40例未经治疗的JAK2V617F阳性MPN患者,以15名健康志愿者为对照组。免疫组化法检测两组骨髓活检组织中磷酸化JAK2(p-JAK2)、基质金属蛋白酶2(MMP-2)、MMP-9的表达水平。选取JAK2V617F阳性MPN患者骨髓细胞,体外应用Ruxolitinib干预,测定干预前后细胞迁移力和MMP-2、MMP-9表达。②不同浓度Ruxolitinib(0、50、100、250、500、1 000 nmol/L)作用于人红白血病细胞株HEL细胞不同时间后CCK-8检测细胞活力,Tanswell小室检测细胞迁移,荧光定量PCR检测JAK2、MMP-2、MMP-9 mRNA水平变化,Western blot检测p-JAK2、MMP-2、MMP-9蛋白表达。 结果: ①MPN组p-JAK2、MMP-2、MMP-9蛋白表达均高于对照组[(78.56±24.55)%对(41.59±17.29)%、(48.25±18.74)%对(22.79±13.89)%、(53.29±19.28)%对(15.56±14.96)%,P值均<0.05]。Spearman相关分析显示MMP-2、MMP-9蛋白水平与JAK2V617F突变量呈正相关(r=0.526, P=0.001;r=0.543, P=0.001)。②Ruxolitinib能够呈时间和剂量依赖性抑制HEL细胞增殖。③迁移实验结果显示5 nmol/L Ruxolitinib作用MPN原代细胞及HEL细胞24 h后迁移至下室细胞数均少于无Ruxolitinib组(154.7±27.5对320.3±67.3,t=13.47,P=0.001;70.7±10.5对135.3±16.7,t=13.89,P=0.001)。④JAK2、MMP-2、MMP-9 mRNA及蛋白表达随Ruxolitinib剂量增加而降低。 结论: Ruxolitinib通过调控JAK2信号通路抑制MMP-2、MMP-9表达而抑制MPN细胞迁移能力。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu GM, Zhang LJ, Fu JZ, et al. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28279039. doi:10.3760/cma.j.issn.0253-2727.2017.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。